# NCT01272037 (NCT01272037)

> Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01272037
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma
- Interventions: Anastrozole; Exemestane; Laboratory Biomarker Analysis; Letrozole; Quality-of-Life Assessment; Systemic Chemotherapy; Tamoxifen Citrate
- Enrollment: 5018
- Primary outcome: Invasive Disease-Free Survival (IDFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 77
- X threads: 61
- Podcasts: 54

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct01272037

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01272037", "email": "<work email>"}; the inbox owner confirms by the emailed link.